• Roivant, Mateon to develop Covid-19 drug candidates pharmaceutical-technology
    March 20, 2020
    Roivant Sciences is in discussion with the US, Europe and Asian regulators to develop gimsilumab for treating acute respiratory distress syndrome (ARDS) caused by Covid-19.
PharmaSources Customer Service